Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Quiflapon sodium (MK591) is a selective inhibitor of 5-Lipoxygenase-activating protein (FLAP).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 549 | 5日内发货 | ||
5 mg | ¥ 925 | 5日内发货 | ||
25 mg | ¥ 4,450 | 6-8周 | ||
50 mg | ¥ 5,790 | 6-8周 | ||
100 mg | ¥ 8,510 | 6-8周 |
Quiflapon sodium 的其他形式现货产品:
产品描述 | Quiflapon sodium (MK591) is a selective inhibitor of 5-Lipoxygenase-activating protein (FLAP). |
体外活性 | Quiflapon sodium is able to block SEB-induced human PBMC cell proliferation. Quiflapon sodium down-regulates three genes (for cathepsin L, IL-17 and guanylate binding protein (GBP)-2) that are up-regulated by SEB [1]. Quiflapon sodium undergoes apoptosis within hours of treatment. Quiflapon sodium also induces rapid activation of the stress kinase, c-Jun N-terminal kinase (JNK), which plays an important role in the apoptosis process. Quiflapon sodium triggers apoptosis in prostate cancer cells without inhibition of PI3K-Akt or ERK. Moreover, MK591 and LY294002 (an inhibitor of PI3K) exert a synergistic effect in inducing apoptosis in prostate cancer cells [2]. Quiflapon sodium (MK591) influences cAMP response element-binding protein but not Sp1[4]. |
体内活性 | Hyperoxia groups of mice treated with Quiflapon sodium (20, 40 mg/kg) show alveolarization that resembles that of room air controls while untreated hyperoxia groups show definite evidence of aberrant alveolarization but no inflammation [3]. A comparison of the Aβ-immunopositive areas between the placebo and Quiflapon sodium (320 mg/kg)-treated group reveals a statistically significant reduction of the amyloid burden in the treated mice. Quiflapon sodium also has a significant reduction in brain levels of IL-1β. Mice treated with Quiflapon sodium show a statistically significant decrease in the steady-state levels of total CREB and its phosphorylated form at Ser133 [4]. |
细胞实验 | LNCaP cells (appr 3×10^5) are plated and treated with inhibitors or solvent vehicle for varying periods of time. Then the cells are lysed in lysis buffer containing 0.2% CHAPS detergent plus protease and phosphatase inhibitors, and the enzymatic activity of Akt is measured by a kit following methods supplied by the manufacturer. |
动物实验 | The Tg2576 transgenic mice expressing human APP with the Swedish mutation (K670N/M671L) are used. They are genotyped by PCR analysis using tail DNA and kept in a pathogen-free environment, on a 12-hour light/dark cycle and have access to food and water ad libitum. All the experiments presented in this paper are performed with female mice. Starting at 7 months of age, mice are randomized to receive MK-591 (40 mg/kg weight) (n=11) or vehicle (n=9) in their chow diet for 8 months until they are 15 months old. Considering that each mouse eats on average 5 g/day of chow diet and the diet is formulated for 320 mg Quiflapon sodium per kg diet, the final dose of the active drug is approximately 40 mg/kg weight/day. During the study, mice in both groups gained weight regularly, and no significant difference in weight is detected between the two groups. No macroscopic effect on the overall general health is observed in the animals receiving active treatment. Post-mortem examination shows no sign of macroscopic pathology in any of the organs considered (spleen, liver, thymus, ileum). |
别名 | 喹夫拉朋钠, MK591 |
分子量 | 610.16 |
分子式 | C34H35ClN2NaO3S |
CAS No. | 147030-01-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
DMSO: 50 mg/mL (82.08 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.6389 mL | 8.1946 mL | 16.3891 mL | 40.9729 mL |
5 mM | 0.3278 mL | 1.6389 mL | 3.2778 mL | 8.1946 mL | |
10 mM | 0.1639 mL | 0.8195 mL | 1.6389 mL | 4.0973 mL | |
20 mM | 0.0819 mL | 0.4097 mL | 0.8195 mL | 2.0486 mL | |
50 mM | 0.0328 mL | 0.1639 mL | 0.3278 mL | 0.8195 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Quiflapon sodium 147030-01-1 Immunology/Inflammation FLAP 喹夫拉朋钠 MK 591 MK591 MK-591 Inhibitor inhibitor inhibit